Literature DB >> 27185341

Analysis of the glutathione S-transferase genes polymorphisms in the risk and prognosis of renal cell carcinomas. Case-control and meta-analysis.

Aiysha Abid1, Sadia Ajaz2, Abdul Rafay Khan2, Fatima Zehra2, Asad Shahzad Hasan3, Gauhar Sultan3, Rehan Mohsin3, Altaf Hashmi3, Najeeb Niamatullah3, Syed Adib-Ul-Hasan Rizvi4, Syed Qasim Mehdi2, Shagufta Khaliq5.   

Abstract

BACKGROUND: The Glutathione S-transferases (GSTs) genes deletion polymorphisms have been associated with the progression of several cancers. The association studies between the 2 GSTs (GSTM1 and GSTT1) null polymorphisms with the susceptibility to renal cell carcinoma (RCC) have been inconclusive. Therefore, with the inclusion of our own data, we performed a comprehensive meta-analysis to assess the association between these 2 polymorphisms and the risk of RCC.
METHODS: A systematic literature search was carried out for studies published in the PubMed, EMBASE, Cochrane library, and Google Scholar from 1997 to December 2014. Results were stated as pooled odds ratios (ORs) for nonparametric data after heterogeneity analysis with 95% CI using fixed effect or random effect model.
RESULTS: We systematically selected 13 relevant studies after thorough searches from the databases. Data showed no association between the GSTM1 and the GSTT1 null genotypes and the risk of RCC (OR = 1.01; CI: 0.92-1.11; P = 0.89 for GSTM1 and OR = 1.14; CI: 0.91-1.42; P = 0.25 for GSTT1). No association was found when the data were stratified according to the geographical/ethnic basis, source of control, and the risk factor evaluation. Subgroup analysis of occupational exposure to pesticides showed an inverse association of the active genotypes of both GSTM1 and GSTT1 polymorphisms with the exposed group of RCC (P<0.00001 and P<0.00001, respectively). The combined null genotype of the GSTM1/GSTT1 significantly increased the susceptibility to RCC by 1.4-fold (P = 0.001). This association remained significant for the Asian populations in subgroup analysis (OR = 1.8; CI: 1.30-2.49; P = 0.0004).
CONCLUSION: In conclusion, this meta-analysis suggests that the 2 GSTs deletion polymorphisms independently have no association with the risk of RCC. However, combination of both deletions increases the risk of developing the RCC.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Glutathione S-transferase genes Polymorphisms; Meta-analysis; Renal cell carcinoma

Mesh:

Substances:

Year:  2016        PMID: 27185341     DOI: 10.1016/j.urolonc.2016.04.005

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  4 in total

1.  A systematic review and meta-analyses of the relationship between glutathione S-transferase gene polymorphisms and renal cell carcinoma susceptibility.

Authors:  Zhiqing Zhong; Hongyan Li; Hongzhen Zhong; Tianbiao Zhou; Weiji Xie; Zhijun Lin
Journal:  BMC Med Genet       Date:  2018-06-08       Impact factor: 2.103

2.  Absence of Glutathione S-Transferase Theta 1 Gene Is Significantly Associated With Breast Cancer Susceptibility in Pakistani Population and Poor Overall Survival in Breast Cancer Patients: A Case-Control and Case Series Analysis.

Authors:  Sadia Ajaz; Sani-E-Zehra Zaidi; Saleema Mehboob Ali; Aisha Siddiqa; Muhammad Ali Memon; Sadaf Firasat; Aiysha Abid; Shagufta Khaliq
Journal:  Front Oncol       Date:  2021-12-06       Impact factor: 6.244

3.  GSTM1 and GSTT1 Polymorphisms and Susceptibility to Prostate Cancer: A Case-Control Study of the Algerian Population

Authors:  Maroua Benabdelkrim; Omar Djeffal; Hajira Berredjem
Journal:  Asian Pac J Cancer Prev       Date:  2018-10-26

4.  GSTO1*CC Genotype (rs4925) Predicts Shorter Survival in Clear Cell Renal Cell Carcinoma Male Patients.

Authors:  Tanja Radic; Vesna Coric; Zoran Bukumiric; Marija Pljesa-Ercegovac; Tatjana Djukic; Natasa Avramovic; Marija Matic; Smiljana Mihailovic; Dejan Dragicevic; Zoran Dzamic; Tatjana Simic; Ana Savic-Radojevic
Journal:  Cancers (Basel)       Date:  2019-12-17       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.